Patidegib hydrochloride is under clinical development by PellePharm and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Patidegib hydrochloride’s likelihood of approval (LoA) and phase transition for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) took place on 27 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Patidegib hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Patidegib hydrochloride overview

Patidegib is under development for the treatment of Gorlin syndrome. The drug candidate is administered orally and applied topically.  It acts by targeting smoothened homolog. It was under development for the treatment of advanced and/or metastatic solid tumor malignancies and pancreatic cancer. It was also under development for the treatment of myelofibrosis and metastatic or locally advanced (unresectable) chondrosarcoma,  basal cell carcinomas.

PellePharm overview

PellePharm, a subsidiary of BridgeBio Inc, is a biotechnology company that develops and commercializes treatments for rare genetic dermatological conditions. The company’s lead clinical program, Patidegib, is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor that treats basal cell carcinomas (BCCs), Gorlin Syndrome and other indications. Patidegib is designed to work by blocking the hedgehog signaling pathway. It enhances chemically a naturally occurring hedgehog pathway inhibitor by preventing the smoothened signal, leading to normal cell function and stopping the excessive production of tumors in patients with Gorlin Syndrome and BCCs. PellePharm is headquartered in San Francisco, California, the US.

Quick View Patidegib hydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Patidegib hydrochloride
Administration Pathway
  • Oral
  • Topical
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: PellePharm
  • Originator: Infinity Pharmaceuticals
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.